US Health Care Professional Perspectives on Adverse Drug Event Reporting in the Hospital Setting and the

Opportunity for Information Technology

Gustavo Grampp Amgen Inc.

!Stella Stergiopoulos, Tufts CSDD; Carrie A. Brown, Tufts University;

Thomas Felix, Amgen Inc.; Kenneth A. Getz; Tufts CSDD

Disclosure - !"#$%#&#'%("$)#&(%*+#)$*,$-"*&$.%#&#,-'/0,$1'&$&2..0%-#)$+3$'$4%',-$5%06$764#,$8,(9$-0$!2:&$;#,-#%$50%$-"#$<-2)3$05$=%24$=#>#?0.6#,-9$$8,-#%.%#-'/0,&$.%0>*)#)$%#.%#&#,-$-"#$&"'%#)$.#%&.#(/>#&$05$-"#$'2-"0%&9$

"!

What is the role of health information technology (HIT) in pharmacovigilance?

•! #$%&'(!)%*!+,!-!+-../,.!*%!.,0%.1)2!-(3,.4,!(.&2!,3,)*4!567849!•! #$%&'(!'/):!0-1,)*!;-.,<!0$-.=-;>!-)(!/)41*&1%)-'!4-?,*>!4>4*,=4!

•! @(,)1A-+',!0-1,)*<!.,0%.*-+',!,3,)*<!4&40,;*!(.&2!540%)*-),%&4!.,0%.*49!

•! #$%&'(!;%=0'>!B/*$!2%3,.)=,)*!0%'/;/,4!-)(!4*-)(-.(4!

•! C.%(&;*D40,;/A;!-)(!+-*;$D40,;/A;!*.-;:/)2!%?!+/%'%2/;-'!0.%(&;*4!

E!

Tufts CSDD 2014 Survey of ADE Reporting Practices in the US

F! @)*,.3/,B,(!GG!,H0,.*4!/)!=,(/;/),<!0$-.=-;>!-)(!/)(&4*.>!

F! I-00,(!678!.,0%.1)2!0.%;,44!J%B4!-)(!K@L!4>4*,=4!/)!$%40/*-'4<!;'/)/;4!-)(!0$-.=-;/,4!

C$-4,!G!

F! M.,-*,(!-)(!(/4*./+&*,(!4&.3,>!/)4*.&=,)*!*%!N#!0.-;11%),.4!/)!3-./%&4!4,O)24!5$%40/*-'<!0$-.=-;><!;'/)/;9!

F! P,;,/3,(!QR!.,40%)4,4!?.%=!$%40/*-'!0.-;11%),.4!50$-.=-;/4*4<!I74<!)&.4,49!

C$-4,!"!

S!

!"#$%&'()*+,--'.&*/'%"0'1%2'3"%&4-#-'

56%"$74#"8'9:,'(%)$,-'%"0';4-9,<-'#"=*&=,0'#"'3>?'@,2*)$"8'

C.-;1;,!.,'-*,(!A)(/)24!-.,!0.,4,)*,(!/)!(*-9,)'(ABC'-*!*$/4!;%)?,.,);,T!

Phase 1 findings related to HIT: Many systems are used in typical hospital practice

8',;*.%)/;!#>4*,=4!

8KPU8IP!

MCV8!

,I6P!

WMI6!

WMIC!

@P!

X!

?&,+9)*"#+';4-9,<-'

8KPU!8IP' 8',;*.%)/;!K,-'*$!P,;%.(4U8',;*.%)/;!I,(/;-'!P,;%.(4!

MCV8' M%=0&*,./Y,(!C$>4/;/-)!V.(,.!8)*.>!4>4*,=!

,I6P' 8',;*.%)/;!I,(/;-1%)!6(=/)/4*.-1%)!P,;%.(!

WMI6' W-.;%(,D,)-+',(!I,(/;-1%)!6(=/)/4*.-1%)!

WMIC' W-.DM%(,!I,(/;-1%)!C.,0-.-1%)!L,;$)%'%2/,4!@P' 8',;*.%)/;!/);/(,)*!.,0%.1)2!4>4*,=!

Phase 2: Survey findings identified a typical Hospital-based ADE reporting process flow

Z!

7.&2!#&40,;*,(!

7.&2!-)(!68!7%;&=,)*,(!/)!C-1,)*!P,;%.(4!

P,*./,3,!7,*-/'4!-+%&*!*$,!7.&2!

P,*./,3,!7,*-/'4!-+%&*!*$,!6(3,.4,!

83,)*!

P,0%.*!6(3,.4,!83,)*!

7.&2!-)(!68!7%;&=,)*,(!/)!@)*,.)-'!@);/(,)*!P,0%.*!

I%4*!.,40%)(,)*4!$-3,!4&+=/[,(!/)*,.)-'!.,0%.*4!5RS\9<!+&*!=-)>!$-(!-'4%!.,0%.*,(!*%!]76!5XG\9!%.!-!=-)&?-;*&.,.!5EX\9^!

^!_&,41%)!B-4!`L%!B$/;$!%?!*$,!?%''%B/)2!%.2-)/Y-1%)4!$-3,!>%&!.,0%.*,(!-)!678a!54,',;*!-''!*$-*!-00'>9b!5)c!XR9!

R!

Phase 2 survey identified key factors preventing ADE reporting in Hospitals!"

D!E'),&%9,0'

@2#&/0,$'&A#)B$CD'&#)$0,$302%$#E.#%*#,(#F$"01$0:#,$)0$#'("$05$-"#&#$%#'&0,&$.%#>#,-$"#'?-"$('%#$.%0>*)#%&$5%06$%#.0%/,4$7=G&$-0$-"#$H=7$0%$-"#$6',25'(-2%#%IJ$5)!c!QR9!

Lack of system integration was cited as a significant reason for not reporting ADEs (52%)*

d,>!(,*-/'4!-.,!40.,-(!-=%)2!=&'10',!(-*-!4%&.;,4!

•!7.&2!(,*-/'4!40.,-(!-;.%44!S!%.!=%.,!4%&.;,4!5SZ\<!)cRS9!

•!678!(,*-/'4!40.,-(!-;.%44!E!%.!=%.,!4%&.;,4!5XG\<!)cZe9!!

Q!

>)68'0,9%#&-'' 3>?'0,9%#&-',I6P!5Ee\9' 8KP!U!8IP!5S"\9'

8KP!U!8IP!5EX\9' @P!#>4*,=!5Ef\9'MCV8!5"X\9'

V*$,.!)%)DK@L!4%&.;,4g!!!C$-.=-;>!5ER\9!!!C-1,)*!M$-.*!5"Q\9!!!C-0,.!+-4,(!@P!5G"\9$

V*$,.!)%)DK@L!4%&.;,4g!!!C-1,)*!;$-.*!5SS\9!!!M-.,!2/3,.!5"Q\9!!!C-0,.!+-4,(!@P!5GG\9$

@,2*)9,0'-*6)+,-'7*)'0,9%#&-''FG'*7'),-2*"0,"9-H'

^_&,41%)!B-4!!`W-4,(!%)!>%&.!,H0,./,);,<!$%B!%h,)!(%!,-;$!%?!*$,4,!.,-4%)4!0.,3,)*!$,-'*$!;-.,!0.%3/(,.4!?.%=!.,0%.1)2!6784!*%!*$,!]76!%.!*$,!=-)&?-;*&.,.a!`!5)cQR9!

Limited availability of important drug data elements in HIT systems

e!i%*,g!i!c!ZET!!_&,41%)!B-4!`j$/;$!%?!*$,!?%''%B/)2!(-*-!-+%&*!*$,!0-.1;&'-.!(.&2!-(=/)/4*,.,(!*%!-!0-.1;&'-.!0-1,)*!-.,!.%&1),'>!-3-/'-+',!/)!>%&.!,',;*.%)/;!4>4*,=4ab!

•! I-)&?-;*&.,.!5A,'(!%.!i7M!;%(,9!-)(!'%*!/(,)1A,.4!-.,!4;-.;,!/)!=%4*!4>4*,=4!•! W-.!;%(,!+-4,(!4>4*,=4!=->!/=0.%3,!(-*-!;-0*&.,!

IJE?K'I>L'/#&&'M,'6-,0'%-'9:,'N;'2)*06+9'#0,"$O,)'#"''9:,'!;J'!>P('

Could HIT impact drug identification in other countries? #$%&!'()*+,!-.!/0123'4!4-'03516'!'4-7+8!5415!'-9+!+:0)+';)3<32=!','5+9'!+2;-()1=+!-)!)+>(3)+!?@@!0)+';)3<32="

Gf!

6.,!4&;$!4>4*,=4!;%=0-1+',!B/*$!*$,!8M!Ck!(/.,;13,a!`!"#!$#%%$#&&'(&')#!*$+*#,-'*,$#'*$!#.*/$!($)0*/123$4%*#'%3$#/3$5)(%(6)4#%$+*0)4)/#%$&'(0-4!$&'*,4')5*07$8)!"$0-*$'*6#'0$!($!"*$/#+*$(2$!"*$+*0)4)/#%$&'(0-4!bG!!

G!M%&);/'!7/.,;13,!"fGfUQSU8M<!-.*T!Gf"5,9<!"fGf!VTlT!5m!ESQ9!RS<!QS!5-=,)(/)2!M%&);/'!7/.,;13,!"ffGUQSU8M9T!

!!

='-'$(02%-#&3$05$H'%6'*,)2&-%*'$E*9%&'M,0-K'QRSTUV'

Can the medicines be looked for by brand?

Is INN only predefined in a drop down menu so that the doctor can select it?

Summary and Discussion

•! K%40/*-'!@L!4>4*,=4!-.,!-)!,44,)1-'!4%&.;,!?%.!.,;%.(/)2!-)(!.,*./,3/)2!678!-)(!4&40,;*!(.&2!/)?%.=-1%)!

•! C.,4,);,!%?!=&'10',!4>4*,=4!*$-*!'-;:!/)*,2.-1%)!=->!+,!-)!%+4*-;',!*%!,n;/,)*!678!.,0%.1)2!

•!I-)>!4>4*,=4!=->!)%*!;-0*&.,!(.&2!/(,)1A,.4!%*$,.!*$-)!+.-)(!-)(U%.!@ii!

•! P,;%==,)(-1%)4g!•! @=0.%3,!-;;,44!*%!/)?%.=-1%)g!!@)*,.%0,.-+/'/*>U/)*,2.-1%)!%?!(.&2!/(,)1A,.4!-)(!678!(-*-!?.%=!=&'10',!4>4*,=4!

•! #>4*,=!(,4/2)4!4$%&'(!0,.=/*!&4,!%?!+.-)(!)-=,4!?%.!+/%'%2/;4!•! @)*,2.-*,!0.%(&;*D40,;/A;!(-*-!?.%=!+-.!;%(,!+-4,(!4>4*,=4!/)*%!%*$,.!K@L!4>4*,=4!*%!/=0.%3,!'%*D',3,'!*.-;,-+/'/*>!

GG!

Limitations

•! L$,!=-o%./*>!%?!$%40/*-'!+-4,(!4&.3,>!.,40%)4,4!%./2/)-*,(!?.%=!E!N#!4*-*,4!5i,B!p%.:<!i,B!l,.4,><!j-4$/)2*%)9!

•! "E\!%?!$%40/*-'!.,40%)(,)*4!5)cX"9!$-(!),3,.!.,0%.*,(!-)!678!5/)*,.)-''>!%.!,H*,.)-''>9!

•! SQ\!$-(!),3,.!.,0%.*,(!-)!678!*%!]76!%.!-!=-)&?-;*&.,.!

G"!

Thank you! q&4*-3%!q.-=00!

6=2,)!@);T!

About the Tufts CSDD

•! M,)*,.!-*!L&h4!N)/3,.4/*>!#;$%%'!%?!I,(/;/),!5$[0gUU;4((T*&h4T,(&9!

•! @)(,0,)(,)*<!-;-(,=/;!2.%&0!?%;&4/)2!%)!(.&2!(,3,'%0=,)*!4;/,)1A;<!.,2&'-*%.><!,;%)%=/;!-)(!=-)-2,=,)*!0%'/;>!

•! q.-)*!?&)(,(!-)(!5;.%44D/)(&4*.>9!40%)4%.,(!4*&(/,4!!

•! P,4&'*4!$-3,!/)?%.=,(!M%)2.,44<!*$,!i-1%)-'!6;-(,=/,4!%?!#;/,);,<!]%&)(-1%)4<!@)(&4*.><!M-0/*-'!I-.:,*!-)-'>4*4!-)(!/)3,4*%.4<!P,2&'-*%.>!62,);/,4<!*$,!i-1%)-'!@)41*&*,4!%?!K,-'*$!

GS!

Tufts CSDD: Furthering the Cause of Pharmaceutical Innovation

!!!!!!

Staff Presentations

Louis Lasagna Library of Drug Development

Electronic Databases &

Bibliographies

!!Sponsorship

!!!

Surveys & Questionnaires

Information Services

Multi-Company Project Series

!!

Manuscripts, White Papers & Book Chapters

!

Research and Publications

!

Industry Programs

Sponsored Research Projects

!!!

Commentaries & Editorials

Tufts CSDD Executive

Forum !!

Public Hearings & Testimony

!

Tufts Center for the Study of Drug Development

Quarterly Updates

!!

Bi-Monthly Impact Report

T U F T S U N I V E R S I T Y !Annual

Postgraduate Course

!!!

Annual Outlook Report

!

Subscription- Based Reports

!

Training & Workshops

Annual Leadership

Course !!!

Quarterly R&D Mgmt. Report

!!

Webinars, Wkshps., & R&D

Roundtables